In two studies, the splicing factors PTBP1 and TRA2A were up-regulated in resistant cells and promoted resistance to gemcitabine in pancreatic cancer through AS regulation of the PKM gene, and to paclitaxel in triple-negative breast cancer through AS of RSRC2, respectively (15,16). This evidence concerns the gene RSRC2 and pancreatic neoplasm.